Wednesday, June 10, 2026

Patent intelligence Β· US

US 2025049789

METHODS OF TREATING ALOPECIA ARAETA

granted A61K 9/ 00 A IA61K 31/ 4985 A IA61K/314985A61K/31519
Status granted
Pipeline programs 6
Years to expiry 19
Applicant portfolio 25
Patent details β€” US 2025049789
Jurisdiction
US
Status
granted
Grant date
Feb 13, 2025
Expiration
Feb 8, 2045
Applicant
ABBVIE INC [US]
CPC classes
A61K 9/ 00 A I, A61K 31/ 4985 A I, A61K/314985, A61K/31519
View on Google Patents β†—

Quick answer

US 2025049789 (METHODS OF TREATING ALOPECIA ARAETA) is held by ABBVIE INC [US]. Status: granted. Granted Feb 13, 2025. Expires Feb 8, 2045 (19 years remaining) β€” relevant for patent-cliff and LOE planning.

Key facts

Applicant
ABBVIE INC [US]
Grant date
Expiration
Claims
β€”
CPC classes
A61K 9/ 00 A I, A61K 31/ 4985 A I, A61K/314985, A61K/31519, A61K/4712, A61K/4726

More from ABBVIE INC [US]

Related pharmaceutical patents in our USPTO index.

  1. AU 2024342196

    NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF

    ABBVIE GROUP HOLDINGS LTD [BM] Β· Expires Mar 28, 2046

    granted
  2. WO 2026039538

    MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS

    TRISHULA THERAPEUTICS INC [US] Β· Expires Feb 14, 2046

    granted
  3. US 20260035439

    Anti-Sars-COV-2 Antibodies and Uses Thereof

    ABBVIE INC [US] Β· Expires Jan 31, 2046

    granted
  4. EP 4670742

    ANTI-CD79B-ANTIKΓ–RPER-WIRKSTOFFKONJUGATE

    ABBVIE INC [US] Β· Expires Dec 26, 2045

    granted
  5. AU 2024276234

    METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES

    ABBVIE MFG MANAGEMENT UNLIMITED COMPANY [IE] Β· Expires Nov 29, 2045

    granted
  6. WO 2025230528

    MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE

    CALICO LIFE SCIENCES LLC [US] Β· Expires Nov 1, 2045

    granted
  7. US 2025333394

    Tiparp Inhibitor Compounds

    ABBVIE INC [US] Β· Expires Oct 25, 2045

    granted
  8. EP 4640274

    LPAR1-INHIBITOREN

    ABBVIE INC [US] Β· Expires Oct 24, 2045

    granted

Frequently asked questions

What is US patent 2025049789?

US 2025049789 (METHODS OF TREATING ALOPECIA ARAETA) is held by ABBVIE INC [US]. Status: granted. Granted Feb 13, 2025. Expires Feb 8, 2045 (19 years remaining) β€” relevant for patent-cliff and LOE planning.

Who owns US 2025049789?

ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 2025049789 expire?

Our index shows an expiration date of Feb 8, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.